EP1514106A4 - TARGETED THERAPEUTIC PROTEINS - Google Patents

TARGETED THERAPEUTIC PROTEINS

Info

Publication number
EP1514106A4
EP1514106A4 EP03736779A EP03736779A EP1514106A4 EP 1514106 A4 EP1514106 A4 EP 1514106A4 EP 03736779 A EP03736779 A EP 03736779A EP 03736779 A EP03736779 A EP 03736779A EP 1514106 A4 EP1514106 A4 EP 1514106A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic proteins
targeted therapeutic
targeted
proteins
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03736779A
Other languages
German (de)
French (fr)
Other versions
EP1514106A1 (en
Inventor
Jonathan H Lebowitz
Stephen M Beverley
William S Sly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Zystor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/272,531 external-priority patent/US20040005309A1/en
Application filed by Zystor Therapeutics Inc filed Critical Zystor Therapeutics Inc
Publication of EP1514106A1 publication Critical patent/EP1514106A1/en
Publication of EP1514106A4 publication Critical patent/EP1514106A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
EP03736779A 2002-05-29 2003-05-29 TARGETED THERAPEUTIC PROTEINS Withdrawn EP1514106A4 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US272531 1994-07-11
US38445202P 2002-05-29 2002-05-29
US384452P 2002-05-29
US38601902P 2002-06-05 2002-06-05
US386019P 2002-06-05
US40881602P 2002-09-06 2002-09-06
US408816P 2002-09-06
US10/272,531 US20040005309A1 (en) 2002-05-29 2002-10-16 Targeted therapeutic proteins
US44573403P 2003-02-06 2003-02-06
US445734P 2003-02-06
PCT/US2003/017211 WO2003102583A1 (en) 2002-05-29 2003-05-29 Targeted therapeutic proteins

Publications (2)

Publication Number Publication Date
EP1514106A1 EP1514106A1 (en) 2005-03-16
EP1514106A4 true EP1514106A4 (en) 2007-05-09

Family

ID=29716364

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03736779A Withdrawn EP1514106A4 (en) 2002-05-29 2003-05-29 TARGETED THERAPEUTIC PROTEINS

Country Status (4)

Country Link
EP (1) EP1514106A4 (en)
AU (1) AU2003237314B2 (en)
CA (1) CA2487815A1 (en)
WO (1) WO2003102583A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003032913A2 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
ATE512674T1 (en) 2003-01-06 2011-07-15 Angiochem Inc ANGIOPEP-1, RELATED COMPOUNDS, AND USES THEREOF
DE602005020745D1 (en) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc ACID ALPHA-GLUCOSIDASE AND FRAGMENTS THEREOF
EP1818395A1 (en) 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA3184105A1 (en) 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc Membrane type-1 matrix metalloprotein inhibitors and uses thereof
RU2011146654A (en) 2009-04-20 2013-05-27 Ангиокем Инк. METHODS FOR TREATING OVARIAN CANCER USING CONJUGATED PRODUCT
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
JP2013507131A (en) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Methods and compositions for increasing iduronic acid 2-sulfatase activity in the CNS
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
JP6045493B2 (en) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Methods and compositions for CNS delivery of arylsulfatase A
BR112012033214B1 (en) 2010-06-25 2020-11-03 Shire Human Genetic Therapies, Inc. use of a stable formulation comprising an iduronate-2-sulfatase protein (i2s), formulation comprising the same and container
CN103269709A (en) 2010-06-25 2013-08-28 夏尔人类遗传性治疗公司 Treatment of sanfilippo syndrome type b
KR20130043165A (en) 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. Methods and compositions for cns delivery of iduronate-2-sulfatase
JP6073783B2 (en) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Methods and compositions for CNS delivery of heparan N-sulfatase
CN104145015A (en) * 2011-12-01 2014-11-12 安吉奥开米公司 Targeted lysosomal enzyme compounds
US20140335163A1 (en) * 2011-12-01 2014-11-13 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
WO2013185235A1 (en) * 2012-06-15 2013-12-19 Angiochem Inc. Targeted iduronidase compounds
ES2679374T3 (en) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
CN104955946A (en) * 2012-11-30 2015-09-30 安吉奥开米公司 Targeted iduronate-2-sulfatase compounds
DK2991683T3 (en) 2013-05-02 2019-11-04 Glykos Finland Oy CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC CHARGE
WO2014194428A1 (en) * 2013-06-06 2014-12-11 Angiochem Inc. Targeted heparan sulfatase compounds
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016065319A1 (en) * 2014-10-24 2016-04-28 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
EP3419651B1 (en) 2016-02-24 2023-10-25 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
JP7458404B2 (en) 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド Purification of iduronic acid-2-sulfatase immunoglobulin fusion protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032913A2 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOLAN C M ET AL: "BINDING OF INSULIN-LIKE GROWTH FACTOR II (IGF-II) BY HUMAN CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR/IGF-II RECEPTOR EXPRESSED IN RECEPTOR-DEFICIENT MOUSE L CELLS", CELL REGULATION, BETHESDA,MD, US, vol. 1, no. 2, January 1990 (1990-01-01), pages 197 - 213, XP008053772, ISSN: 1044-2030 *
See also references of WO03102583A1 *

Also Published As

Publication number Publication date
EP1514106A1 (en) 2005-03-16
CA2487815A1 (en) 2003-12-11
AU2003237314B2 (en) 2010-03-04
AU2003237314A1 (en) 2003-12-19
WO2003102583A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
DK1543038T4 (en) Protein purification
ATE465180T1 (en) THERAPEUTIC ANTI-IGFR1 ANTIBODIES COMBINATIONS
IS7499A (en) Human antibodies against beta-amyloid peptides
EP1691718A4 (en) THERAPEUTIC MICROPARTICLES
ATE480567T1 (en) HIGHLY CONCENTRATED ANTIBODIES AND PROTEIN FORMULATIONS
EP1379132A4 (en) HUMAN SECRETED PROTEINS
NO20040402L (en) Peptide-based multimeric targeting agents
EP1597276A4 (en) THERAPEUTIC MOLECULES
EP1391209A4 (en) PROTEIN FORMULATIONS
EP1460900A4 (en) SEPARATE HUMAN PROTEINS
EP1570270A4 (en) THERAPEUTIC BIOCONJUGATES
EP1556403A4 (en) ENGINEERING MULTIMERIC PROTEINS
DK1597171T3 (en) THERAPEUTIC MICROSUM
EP1578774A4 (en) PURIFICATION OF PROTEINS
DE60334272D1 (en) heater
DK1553950T3 (en) Therapeutic treatment
DE10391058D2 (en) Instantized modified flours
NO20050689L (en) Therapeutic use
EP1682572A4 (en) EXPRESSION OF PROTEINS
FR2839258B1 (en) Walker SEE
NO20053512D0 (en) IL-8-like proteins
NO20050436D0 (en) Beta-layer-breaking peptides
NO20052608D0 (en) Midkin-like protein
ATA522002A (en) VMP-BINDING PROTEIN
SE0200450D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076863

Country of ref document: HK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BEVERLEY, STEPHEN, M.

Inventor name: SLY, WILLIAM, S.

Inventor name: LEBOWITZ, JONATHAN, H.

A4 Supplementary search report drawn up and despatched

Effective date: 20070405

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOMARIN PHARMACEUTICAL INC.

17Q First examination report despatched

Effective date: 20121031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130312

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076863

Country of ref document: HK